Heng Cai

Heng Cai


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
XWXiaoyan Wang
Xiaoyan Wang
YXYang Xu
Yang Xu
CPChongzhe Pei
Chongzhe Pei
HZHongmei Zheng
Hongmei Zheng
HCHeng Cai
Heng Cai
The escalating global burden of cardiovascular disease (CVD) necessitates a deeper elucidation of the fundamental molecular mechanisms driving its pathogenesis. Aberrant immune activation, specifically sterile inflammation, is now recognized as a core hallmark of CVD, predominantly ignited by the pathological accumulation of damaged self-DNA. As the principal cytosolic DNA sensor, the cyclic GMP-AMP synthase (cGAS)–stimulator of interferon genes (STING) pathway has emerged as a crucial mechanistic nexus translating genomic distress into robust innate immune responses. Despite its paramount importance, a comprehensive integration of how DNA damage-induced cGAS-STING activation orchestrates cardiovascular immunology remains underexplored. In this review, we comprehensively synthesize the dynamic immunological landscape of CVD, with a specific focus on the critical interplay between DNA damage and sterile inflammation. We delineate the intricate molecular cascades of the cGAS-STING pathway across diverse cardiovascular pathologies and critically evaluate its role as a master amplifier of disease progression. Furthermore, we highlight the translational trajectory of targeting the cGAS-STING axis, emphasizing how deciphering this DNA damage-immune network provides a rational blueprint for developing precision immunomodulatory therapies in cardiovascular medicine.

24 January 2026 in JACC: Case Reports
Verified
Journal Article
Open access
HZHongmei Zheng
Hongmei Zheng
CPChongzhe Pei
Chongzhe Pei
DLDong Li
Dong Li
HLHongshi Li
Hongshi Li
LXLi Xue
Li Xue
HCHeng Cai
Heng Cai
Congenital interruptions of the inferior vena cava (IVC) and persistent left superior vena cava (PLSVC) are rare. When combined with dextroversion, they pose significant challenges for catheter ablation. A 65-year-old man with 2-year palpitations (worsened for half a month) had typical atrial flutter and dextroversion on ECG. Echocardiography showed PLSVC; computed tomography angiography confirmed IVC interruption. Ablation was successfully performed via a left superior venous approach with 3D mapping, targeting the cavotricuspid isthmus between the tricuspid annulus and hepatic vein. This is the first reported case of atrial flutter ablation in a patient with coexisting dextroversion, PLSVC, and IVC interruption. It highlights the importance of anatomical recognition and adaptive strategies. Preprocedural imaging is crucial in cardiac malformation. Alternative access routes and 3D mapping are key to successful ablation in complex anatomy.

16 October 2026 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
XXXinyu Xu
Xinyu Xu
YLYunfan Li
Yunfan Li
FLFengmin Lu
Fengmin Lu
HLHuanming Li
Huanming Li
HCHeng Cai
Heng Cai
Background: Pulsed field ablation (PFA) is a non-thermal, tissue-selective therapy for atrial fibrillation. In this study, we evaluated the safety and efficacy of a novel asymmetric biphasic PFA system, which combines a unique pulse-parameter configuration with a dedicated, adjustable six-spline catheter. Methods: This prospective, multicenter, single-arm study was conducted in China. Patients with drug-refractory paroxysmal AF underwent pulmonary vein isolation (PVI) using a 1,000 V asymmetric biphasic PFA system with a novel parameter configuration. The primary effectiveness endpoint was freedom from atrial arrhythmia recurrence through 12 months post-blanking. The primary safety endpoint was predefined serious adverse events. The secondary safety endpoint was hemolysis and silent cerebral lesions (SCLs). Results: Among 120 enrolled patients, 105 underwent ablation and completed the 12-month follow-up, while 15 patients withdrew before the PFA operation. Acute PVI was successfully achieved in all 420 targeted veins. At 12 months, the Kaplan–Meier estimate of freedom from atrial arrhythmia recurrence was 69.5% (95% CI, 60.1–77.5%). The observed 12-month effectiveness was within the range reported in previous studies of PFA technologies. Regarding safety, major procedural complications—including pulmonary vein stenosis, phrenic nerve injury, atrioesophageal fistula, stroke, and acute kidney injury (AKI)—were entirely absent. However, one patient (0.95%) experienced a transient coronary vasospasm that was successfully resolved with an intracoronary vasodilator. Additionally, SCLs were detected in two patients (1.9%). While laboratory hemolysis was a common finding, it did not lead to renal impairment. Conclusions: This asymmetric biphasic PFA system achieved complete acute PVI and 12-month effectiveness was within the range reported in previous studies of PFA technologies. It showed a favorable safety profile, with few SCLs and no hemolysis-related AKI. Clinical Trial Registration: https://www.chictr.org.cn/showproj.html?proj=134973 , identifier ChiCTR2200062157.

25 May 2026 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
CPChongZhe Pei
ChongZhe Pei
KYKuan Yang
Kuan Yang
XDXin Ding
Xin Ding
HLHongshi Li
Hongshi Li
LXLi Xue
Li Xue
HCHeng Cai
Heng Cai
This study investigates the association between the neutrophil percentage-to-albumin ratio (NPAR) and mortality in takotsubo syndrome (TS) patients. We conducted a retrospective cohort study using data from the MIMIC-IV version 3.1 database. Multivariable Cox regression and restricted cubic spline (RCS) analyses were performed to evaluate the associations between NPAR and 28-day, 180-day, and 365-day mortality. Predictive performance for 28-day mortality was assessed using receiver operating characteristic (ROC) analysis and seven machine-learning models. A total of 201 patients with TS were included. Higher NPAR was independently associated with increased 28-day mortality (HR 5.494, 95% CI 1.939-12.190, P < 0.001), 180-day mortality (HR 5.141, 95% CI 2.367-11.166, P < 0.001), and 365-day mortality (HR 5.280, 95% CI 2.439-11.429, P < 0.001). RCS analysis showed a significant overall association between NPAR and 28-day mortality (P for overall = 0.041), without significant nonlinearity (P for nonlinear = 0.194). NPAR showed modest predictive ability for 28-day mortality (AUC 0.640). In machine-learning analyses, NPAR was identified as an important prognostic feature, and the random forest model achieved the highest AUC (0.771). Higher NPAR values are associated with increased mortality rates at 28-day, 180-day, and 365-day intervals in TS patients, suggesting NPAR as a potential predictive marker for TS outcomes.